Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

AZN revenue ambitions hit by psoriasis drug setback

AZN news

June 1:
Deutsche Bank : Hold - TP: 4850p
Jefferies: Buy - TP: 5600p

June 2:
Jun Kepler Cheuvreeaux: Reduce - TP: 3700p
Exane BNP.: Outperform - TP: .5800p
JP Morgan: Neutral - TP: 4300p

Questor/Telegraph: Hold

JP Morgan: Neutral - TP up from 4300p to 4400p

June 26: HSBC new coverage: Hold - TP: 4640p

Questor/Telegraph: Buy

July 6: Jefferies: Buy - TP: 5600p

July 7: Oddo Securities - new coverage: Reduce - TP: 4400p

July 13: Jefferies Buy - TP down from 5600p to 5400p

FDA approves lung cancer treatment

StockMarketWire.com
AstraZeneca's core operating profits fell to $3,618m in the first half - 4% down 4% at constant exchange rates.

Total revenues were up 1% at constant rates at $12,364m and reported operating profits rose by 1% at constant rates to $1,856m.

The group said its robust top-line performance, supported by externalisation, underpins accelerated investment in R&D to progress pipeline, up 24% in H1.

Highlights:
· Core SG&A efficiency programme - early progress: Core SG&A 35% of Q2 Total Revenue (Q4 2014: 44%) - Sales & marketing effectiveness, centralisation of functions, process improvements, third-party spend, further efficiencies across support areas, footprint optimisation

· Core H1 EPS stable, up 3% in Q2, enhanced by one-off tax benefit

· FY 2015 Total Revenue guidance at CER improved: Now expected to decline by low single-digit percent (prior guidance - mid single-digit). Core EPS guidance at CER is unchanged: Expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D

· The Board recommends an unchanged first interim dividend of $0.90

Chief executive Pascal Soriot said: "We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas.

"I'm particularly pleased by the pace of progress in Oncology, with new approvals for both Iressa and Faslodex accompanied by regulatory submissions for AZD9291 and cediranib. The strong performance of the growth platforms and the subsequent upgrade to top-line guidance, together with increased R&D productivity reaffirm the confidence we have in our ability to navigate the final impacts from the loss of exclusivity and meet our revenue targets."

July 30:
Barclays: Underweight - TP: 4400p
Jefferies: Buy - TP: 5400p

Aug 10: Citigroup: Buy - TP: 5400p

Aug 18:
Credit Suisse: Neutral - TP: 4320p
JP Morgan: Neutral - TP: 4400p

With their older drugs and delivery system effectively in the hands of Generics, AZN has at last found a drug that's potentially a Blockbuster ( So I read in IC ). This prob. explains why the sp has rocketed recently - "All Hope" - but it's still too much at £50-a pop for me. +Good-Luck to all who sail in her....

For some may be worth a review.

Present price 4671p


Target price

Date Broker New target Recomm.
28 Feb Bryan Garnier 5,400.00 Buy
27 Feb Exane BNP... 5,300.00 Neutral
22 Feb Berenberg 5,450.00 Buy

-=-=-==


"TIDMAZN

RNS Number : 0243Y

AstraZeneca PLC

28 February 2017

This announcement contains inside information

28 February 2017 07:00 GMT

FDA APPROVES ONCE-DAILY QTERN (DAPAGLIFLOZIN AND SAXAGLIPTIN) TABLETS FOR ADULTS WITH TYPE-2 DIABETES

Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level"



-=-=-=--=-=


TIDMAZN

RNS Number : 8210X

AstraZeneca PLC

24 February 2017

This announcement contains inside information

"24 February 2017 12:30 GMT

ZS-9 (sodium zirconium cyclosilicate) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HYPERKALAEMIA

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia, a serious condition characterised by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases."

AZ lung cancer drug gets US approval

StockMarketWire.com

AstraZeneca's lung cancer drug Tagrisso has been granted full approval by the US Food and Drug Administration.

AstraZeneca's said the FDA had approved Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy.

StockMarketWire.com
AstraZeneca has reiterated its full-year guidance following a first half performance in line with forecasts.

The group said the residual effects of the Crestor and Seroquel XR loss of exclusivity in the US had an impact on product sales which fell to $9,783m - down 11% at actual exchange rates.

Total revenues of $10,456m were down 11% at actual exchange rates and 10% at constant currencies.

Reported operating profit rose to $1,842m - up 37% at actual exchange rates and 22% at constant currencies.

Core operating profits of $3,215m wer eup 7% at actual exchange rates and 3% at constant currencies.

The first half dividend is maintained at $0.90 per share.

Chief executive Pascal Soriot said: "Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US.

"We continued to deliver transformative science across the pipeline, particularly in Oncology.

"Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our first-in-class PARP inhibitor.

"In lung cancer, we strengthened our unique portfolio focused on both the genetic drivers of disease and immunotherapy. In the first half, we shared positive results for Imfinzi in the PACIFIC trial and reported more encouraging data for Tagrisso in patients with central nervous system metastases.

"I'm excited about our pipeline-driven transformation as we continue to deliver for shareholders on our strategy to return to sustainable long-term growth.

"In a pivotal year for AstraZeneca, we remain focused on realising the potential of our pipeline, growing our new launch medicines and bringing our strong science to patients."

HARRYCAT, you forgot to mention the Drug-failure...hit sp 16%
Q. Is this a Buying Opportunity (Yield ~4%)....or wait and see if it falls further....as the lower TO on existing products is factored-in. This must be a grim time for LT investors have seen the Stock rise from £40 to ~£50 since only Dec.2016( That's +25% in 8 Months !).
- Presumably in the hope that replacement Drug-products will offset the loss of Patent-protection, due to expiry. Now it's not-so there could be further fall from £43 to £40....
EDIT ( 28July2017)- cynic....it's always been "too expensive" for me... and recent fall hardly changes that..... Maybe at £20 I would want some, for the LT revenue, assuming some drug-replacement will occur in time. Ut's human nature for Div-Chiefs to praise themselves for current products....whereas they should be attentive to 10-years on....